For example, there can be no assurance that other trials or evaluations of SAGE or other product candidates will be favorable or that they will confirm results of previous studies, that data evaluation will be completed or demonstrate any hypothesis or endpoint, that SAGE or other product candidates will provide utility or benefits to certain patients, that any presentations will be favorably received, that SAGE or other product candidates will be useful, that marketing applications will be filed or, if filed, approved, or that clinical or Ligand phamaceuticals essay development of these product candidates will be initiated, completed or successful or that our rights relating to Captisol, SAGE and other related product candidates will not be successfully challenged.
By diversifying the portfolio of assets across numerous technology types, therapeutic areas, drug targets and industry partners, we offer investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry.
In comparison to its peers, we believe Ligand has assembled one of the largest and most diversified asset portfolios in the industry with the potential to generate revenue in the future.
Captisol was invented and initially developed by scientists in the laboratories of Dr. There are more than 30 Captisol-enabled products currently in clinical development. Additional information concerning these and other risk factors affecting Ligand can be found in prior press releases available at www.
These forward-looking statements include comments regarding SAGE and other drug candidates, data analysis and evaluation of SAGE, utility or potential benefits to patients, the potential commercial market for SAGE and plans for continued development and further studies of SAGE Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this press release.
This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of About Ligand Pharmaceuticals Ligand is a biopharmaceutical company with a business model focused on developing or acquiring royalty generating assets and coupling them with a lean corporate cost structure.Essay on nickel complex from Schiff base ligand Abstract Pyrorlealdehyde and 1,3-diaminopropane react under reflux to form a transition metal ion of Nickel(II), that further more react with nickel acetate to form red crystals through condensation, the colour being constituded by the congugated bonds.
Welcome to Ligand Pharmaceuticals. Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Free Essay: Describe what you believe is implied by the term “engagement risk.” What are the key factors likely considered by Deloitte and other audit firms.
Read this essay on Ligand Pharmaceuticals. Come browse our large digital warehouse of free sample essays. Get the knowledge you need in order to pass your classes and more.
Only at mint-body.com". Essay about Ligand Case Words | 6 Pages. supervisory roles in auditing public audit firms and individual auditors.
This was done through establishment of proper quality control measures on the work of auditors to minimize the audit risks that firms could face while conducting their work.
Ligand Earns Milestone from SAGE Therapeutics for SAGE Download as PDF. Ligand entered into a Captisol license agreement with SAGE for the development and commercialization of SAGE in SAGE is in development by SAGE Therapeutics for the treatment of SRSE.Download